CLL

expert roundtables

by Jennifer R. Brown, MD, PhD, Bruce D. Cheson, MD, FACP, FAAAS, FASCO, Susan O’Brien, MD

The treatment approach in older patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is evolving due to the emergence of novel agen......READ MORE

expert roundtables

by Jennifer R. Brown, MD, PhD, Bruce D. Cheson, MD, FACP, FAAAS, FASCO, Susan O’Brien, MD

Patients with chronic lymphocytic leukemia (CLL) are complicated in their humoral and cellular immunodeficiency. While no CLL therapy is viewed as ......READ MORE

patient care perspectives

by Susan O’Brien, MD

The treatment of elderly patients with chronic lymphocytic leukemia and comorbid conditions requires an assessment of individual patient factors an......READ MORE

clinical topic updates

by Susan O’Brien, MD

Both clonal and subclonal TP53 mutations can be important predictors of survival in patients with chronic lymphocytic leukemia (CLL). Recent data s......READ MORE